Please use this identifier to cite or link to this item:
|Title:||Clinical pharmacokinetics of alamifovir and its metabolites|
|Citation:||Chan, C., Abu-Raddad, E., Golor, G., Watanabe, H., Sasaki, A., Yeo, K.P., Soon, D., Sinha, V.P., Flanagan, S.D., He, M.M., Wise, S.D. (2005-05). Clinical pharmacokinetics of alamifovir and its metabolites. Antimicrobial Agents and Chemotherapy 49 (5) : 1813-1822. ScholarBank@NUS Repository. https://doi.org/10.1128/AAC.49.5.1813-1822.2005|
|Abstract:||Alamifovir, a purine nucleotide analogue prodrug, and its hydrolyzed derivatives have shown preclincal efficacy activity against wild-type and lamivudine-resistant hepatitis B virus. Two studies were conducted to examine the single- and multiple-dose alamifovir pharmacokinetics after oral administration in healthy males. In study 1, subjects were given single doses (0.2 to 80 mg), with a subset receiving 20 mg in a fed state. Study 2 subjects were dosed with 2.5 to 15 mg twice daily for 15 days. Plasma samples were collected over 72 h in study 1 and over 24 h on days 1 and 15 in study 2. Concentrations of alamifovir and its major metabolites were determined using liquid chromatography/tandem mass spectrometry methods. The data were analyzed using a noncompartmental technique. Although alamifovir was rapidly absorbed, there was limited systemic exposure due to its rapid hydrolysis and formation of at least three metabolites, suggesting that alamifovir acts as a prodrug. The major metabolites detected were 602074 and 602076, with 602075 detectable only in higher-dose groups. Maximum 602074 plasma concentration was achieved at approximately 0.5 h (Tmax) and declined with a 1- to 2-h terminal half-life (t1/2). Maximum concentrations of 602076 (Cmax) averaged 10% of the 602074 Cmax and reached Tmax in 2.5 h with a 4-h t1/2. Food appeared to decrease the extent of absorption of the compound. Multiple dosing resulted in minimal accumulation, and the concentrations following multiple doses could be predicted using the single-dose data. Alamifovir was well tolerated and the pharmacokinetics were characterized in these studies. Copyright © 2005, American Society for Microbiology. All Rights Reserved.|
|Source Title:||Antimicrobial Agents and Chemotherapy|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 21, 2019
WEB OF SCIENCETM
checked on Jan 2, 2019
checked on Aug 3, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.